Compare WAY & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | HAE |
|---|---|---|
| Founded | 1999 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2023 | 1996 |
| Metric | WAY | HAE |
|---|---|---|
| Price | $24.67 | $86.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $36.59 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 2.9M | 720.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 569.23 | N/A |
| EPS | 0.43 | ★ 0.72 |
| Revenue | ★ $1,099,278,000.00 | $910,373,000.00 |
| Revenue This Year | $18.26 | N/A |
| Revenue Next Year | $10.62 | $5.23 |
| P/E Ratio | ★ $56.35 | $122.00 |
| Revenue Growth | ★ 16.50 | N/A |
| 52 Week Low | $17.26 | $47.32 |
| 52 Week High | $39.99 | $88.59 |
| Indicator | WAY | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 65.96 |
| Support Level | $23.79 | $78.87 |
| Resistance Level | $24.67 | $87.34 |
| Average True Range (ATR) | 1.06 | 2.85 |
| MACD | 0.13 | 0.26 |
| Stochastic Oscillator | 87.70 | 85.19 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.